



Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.

Journal: Cell

Publication Year: 2022

Authors: Tzu-Tang Wei, Mark Chandy, Masataka Nishiga, Angela Zhang, Kaavya Krishna Kumar, Dilip

Thomas, Amit Manhas, Siyeon Rhee, Johanne Marie Justesen, Ian Y Chen, Hung-Ta Wo, Saereh Khanamiri, Johnson Y Yang, Frederick J Seidl, Noah Z Burns, Chun Liu, Nazish Sayed, Jiun-Jie

Shie, Chih-Fan Yeh, Kai-Chien Yang, Edward Lau, Kara L Lynch, Manuel Rivas, Brian K

Kobilka, Joseph C Wu

PubMed link: 35489334

Funding Grants: CIRM Bridges 2.0: Training the Next Generation of Stem Cell Scientists

Public Summary:

Epidemiological studies reveal that marijuana increases the risk of cardiovascular disease (CVD); however, little is known about the mechanism. Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD. A UK Biobank analysis found that cannabis was an risk factor for CVD. We found that marijuana smoking activated inflammatory cytokines implicated in CVD. In silico virtual screening identified genistein, a soybean isoflavone, as a putative CB1 antagonist. Human-induced pluripotent stem cell-derived endothelial cells were used to model Delta(9)-THC-induced inflammation and oxidative stress via NF-kappaB signaling. Knockdown of the CB1 receptor with siRNA, CRISPR interference, and genistein attenuated the effects of Delta(9)-THC. In mice, genistein blocked Delta(9)-THC-induced endothelial dysfunction in wire myograph, reduced atherosclerotic plaque, and had minimal penetration of the central nervous system. Genistein is a CB1 antagonist that attenuates Delta(9)-THC-induced atherosclerosis.

Scientific Abstract:

Epidemiological studies reveal that marijuana increases the risk of cardiovascular disease (CVD); however, little is known about the mechanism. Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the psychoactive component of marijuana, binds to cannabinoid receptor 1 (CB1/CNR1) in the vasculature and is implicated in CVD. A UK Biobank analysis found that cannabis was an risk factor for CVD. We found that marijuana smoking activated inflammatory cytokines implicated in CVD. In silico virtual screening identified genistein, a soybean isoflavone, as a putative CB1 antagonist. Human-induced pluripotent stem cell-derived endothelial cells were used to model Delta(9)-THC-induced inflammation and oxidative stress via NF-kappaB signaling. Knockdown of the CB1 receptor with siRNA, CRISPR interference, and genistein attenuated the effects of Delta(9)-THC. In mice, genistein blocked Delta(9)-THC-induced endothelial dysfunction in wire myograph, reduced atherosclerotic plaque, and had minimal penetration of the central nervous system. Genistein is a CB1 antagonist that attenuates Delta(9)-THC-induced atherosclerosis.

Source URL: https://www.cirm.ca.gov/about-cirm/publications/cannabinoid-receptor-1-antagonist-genistein-attenuates-marijuana-induced